EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy

Luciano Severgnini, Bernd Hartmann, Doz. Thomas Winder, Theresia Lang, Andreas Volgger, Magdalena Benda, Patrick Reimann

Case Reports in Oncology · 2026-08-22 · 19 (1) · 1512-1523

DOI: 10.1159/cro/abzag009 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Medullary thyroid carcinoma (MTC) is a rare, but aggressive tumor that accounts for 4% of thyroid carcinomas. A mutation in the proto-oncogene RET has been shown to occur in ca. 70% of those neoplasia. Selpercatinib is a newly approved drug that specifically targets the RET-kinase and demonstrated a very high efficacy in reducing the tumor activity and in progression-free survival in patients with an advanced metastatic disease [1]. Case Presentation: In accordance with the approval of the FDA, we started a treatment with selpercatinib on 2 patients with advanced metastatic MTC with an established RET mutation. They received selpercatinib 160 mg bidaily, and we observed the patients for 60 months. We observed a very good metabolic and serological response to the treatment with a decrease in the tumor marker of 99.8% and 98.5% and stable imaging. Hypertension grade II, hypotension grade I, proteinuria grade I, hyperphosphatemia grade I, and hypocalcemia grade II were the low-grade side effects that we observed during these 60 months of therapy. Conclusion: Selpercatinib proved to be a good antineoplastic drug for patients with RET-mutated, advanced, and inoperable MTC.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →